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STUDY QUESTION: Does an individualized serum anti-Müllerian hormone (AMH) based FSH dosing algorithm used in a GnRH antagonist
protocol increase the proportion of patients with an intended number of oocytes (5–14) retrieved compared with a standard regimen?
SUMMARY ANSWER: The AMH-based individualized algorithm did not increase the proportion of patients with an intended oocyte
retrieval.
WHAT IS KNOWN ALREADY: Individualizing treatment for ovarian stimulation by serum AMH or antral follicle count can theoretically
improve the ratio between beneﬁts and risks. Current data suggest that there may be a reduced risk of ovarian hyperstimulation syndrome
(OHSS), but without improved pregnancy or live birth rates. Only two randomized controlled trials (RCTs) have examined the potential of
AMH-based algorithms to optimize the FSH dosing in ovarian stimulation.
STUDY DESIGN, SIZE, DURATION: A dual-center open-label investigator-driven RCT was conducted between January 2013 and
November 2016. Eligibility was assessed in 269 women and 221 were randomized 2:1 between individualized and standard dosing groups.
Women with pretreatment serum AMH > 24 pmol/L had 100 IU/day of recombinant FSH (rFSH); AMH 12–24 pmol/L had 150 IU/day of
rFSH, and AMH < 12 pmol/L had maximal stimulation with corifollitropin 100 or 150 mg depending on bodyweight ±60 kg. The standard
group had 150 IU/day of rFSH irrespective of pretreatment AMH. All patients followed the GnRH-antagonist protocol.
The sample size calculation assumed that individualized dosing by AMH would reduce the proportion of unintended oocyte yield (outside
the 5–14 range) by 50%, from 35 to 17.5%. In a 2:1 randomization this required 216 patients: 144 in the individualized and 72 patients in the
standard group (80% power, 5% signiﬁcance).
PARTICIPANTS/MATERIALS, SETTING, METHODS: All women had a presumed ovulatory normal menstrual cycle, were aged
25–38 years, weighed < 75 kg, had pretreatment AMH 4–40 pmol/L, did their ﬁrst IVF or ICSI cycle and had two ovaries accessible to oocyte
retrieval. Recruitment was conducted from both participating sites. Women were excluded if diagnosed with anovulatory polycystic ovary
syndrome, endometriosis grade III/IV, hydrosalpings on ultrasound, recurrent miscarriages (≥3), FSH > 12 IU/L or major medical disorders.
MAIN RESULTS AND THE ROLE OF CHANCE: After randomization 149 women were allocated to the individualized group and 72 to
the standard group. The primary outcome of women with an intended (5–14) number of oocytes retrieved was similar in the individualized
(n = 105) versus the standard (n = 55) rFSH treatment group (72% [95% CI 64–79%] versus 78% [95% CI 67–86%], respectively, P = 0.68,
between group standardized mean difference (SMD) −6%, 95% CI: −19–8%). In the high AMH stratum of the individualized group, signiﬁ-
cantly more women (n = 13) had an unintended low number of oocytes (<5) retrieved (38% [95% CI: 23–55%]) compared with the standard
group (6% [95% CI 0.3–24%], P = 0.029, between group SMD 32%, 95% CI: 9–56%). Conversely, in the low pretreatment AMH stratum,
individualized dosing using corifollitropin reduced the proportion of unintended low responders to 24% (95% CI: 12–40%) compared with
47% (95% CI: 26–69%) in the standard group, P = 0.10, between group SMD −23% (95% CI: −54–8%). OHSS was diagnosed in four women
(two in each study arm), and all cases were mild. Daily luteal phase questionnaire reporting showed similar wellbeing in terms of abdominal
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distention, abdominal pain, dyspnea and occurrence of bleeding between groups. The cumulative live birth rate per started cycle was similar
(32 and 35%) comparing the individualized with the standard group.
LIMITATIONS, REASONS FOR CAUTION: This study was powered for showing differences only in the distribution of oocyte retrieval
when comparing individualized and standard groups, therefore additional results should be viewed with caution. In addition, there was a
change of AMH assay halfway through the study period and the possibility that corifollitropin being introduced to a subgroup of the interven-
tion has introduced confounding cannot be ruled out.
WIDER IMPLICATIONS OF FINDINGS: In the expected high responder AMH stratum, 100 IU/day is an insufﬁcient rFSH dose in a high
proportion of patients. Further research might explore the 125 IU/day dose for the high AMH segment.
STUDY FUNDING/COMPETING INTEREST(S): None for the submitted work. ICMJE declared personal interests for two of the
authors.
TRIAL REGISTRATION NUMBER: EUDRACT registration number: 2012-004969-40.
TRIAL REGISTRATION DATE: 27 November 2012.
DATE OF FIRST PATIENT’S ENROLLMENT: 10 January 2013.
Key words: individualized FSH dosing / anti-Müllerian hormone / ovarian stimulation / FSH / randomized controlled trial / ovarian
response / oocyte retrieval
Introduction
Individualized FSH dosing using antral follicle count (AFC) or anti-
Müllerian hormone (AMH) as ovarian reserve tests (ORT) has been
introduced to optimize the ratio between beneﬁts and risks of ovarian
stimulation for IVF. Theoretically, individualized dosing could provide
the targeted number of oocytes, which in turn could increase the preg-
nancy rate and lower the risk of ovarian hyperstimulation syndrome
(OHSS). Earlier randomized controlled studies (RCTs) of individua-
lized dosing targeted the retrieval of 9–11 oocytes, ranging from 5 to
14 or 8 to 14 (Popovic-Todorovic et al., 2003; Olivennes et al., 2015;
Allegra et al., 2017; Nyboe Andersen et al., 2017). The recently pub-
lished large Dutch optimization of cost effectiveness through
Individualized FSH Stimulation dosages for IVF Treatment: A rando-
mized trial (OPTIMIST trials) (Oudshoorn et al., 2017; van Tilborg
et al., 2017a,b) used AFC as the ORT and found that individualization
did not increase pregnancy rates, but may reduce the risk of OHSS
(Oudshoorn et al., 2017).
Apart from the recent Evidence-based Stimulation Trial With
Human rFSH in Europe and Rest of World (ESTHER) trial (Nyboe
Andersen et al., 2017), earlier RCTs on individualized dosing have
mainly used the long GnRH agonist protocol. There is a need for stud-
ies examining individualized dosing in the short GnRH antagonist
protocol that is used more frequently today due to a more positive
patient experience as well as a better balance between risk in terms of
OHSS (Toftager et al., 2016) and beneﬁt in terms of cumulative live
birth rates (Toftager et al., 2017).
Currently, the best biomarkers for response prediction seem to be
AMH and AFC. Both predict low and excessive responses to ovarian
stimulation (Broer et al., 2009), but AFC may have higher inter-observed
variability between clinics in multicenter trials and may therefore be a less
appropriate parameter to use (Nelson et al., 2015a). Additionally, the
clinical use of AMH-based dosing models (La Marca and Sunkara, 2014)
has been tested, ﬁrstly in observational studies (Nelson et al., 2009; Yates
et al., 2011) and recently in RCTs (Allegra et al., 2017; Nyboe Andersen
et al., 2017). This development has been facilitated by the new fully auto-
mated assay for AMH measurements, providing faster and more repro-
ducible results than the earlier ELISA methods (Nelson et al., 2015b).
Based on the currently available evidence (Nyboe Andersen et al.,
2017; Oudshoorn et al., 2017; van Tilborg et al., 2017a,b; Lensen
WHATDOES THIS MEAN FOR PATIENTS?
Women who seek assisted reproduction treatment for IVF typically undergo hormonal ovarian stimulation with follicle stimulating hormone
(FSH) to develop a reasonable number of mature follicles containing healthy eggs. Retrieval of 5–14 egg cells from a single cycle balances the
chance of a live birth versus the risk of ovarian hyperstimulation syndrome (OHSS).
Hormonal stimulation algorithms using ovarian reserve tests (ORT) have been introduced to increase the proportion of women who develop
an appropriate number of eggs. Using the anti-Müllerian hormone (AMH) level in serum before treatment as an ORT, this study divided partici-
pants into expected low (AMH < 12 pmol/L), medium (AMH 12–24 pmol/L) and high (AMH > 24 pmol/L) response groups. The participants
were randomized to receive either low, normal or high FSH doses for ovarian stimulation based on their AMH. The standard group all had
150 IU/day of FSH irrespective of their AMH level.
The AMH-based stimulation did not increase the proportion of women who reached the intended target of eggs. Conversely, in the expected
high response group a statistically signiﬁcant proportion of women developed unintended few egg cells, because the low dose of 100 IU of FSH/
day was insufﬁcient.
Patients should be informed that dosing with 150 IU/day of FSH is recommended, but patients with high ORTs, such as AMH, could be dosed
with around 125–137 IU/day to reduce their risk of OHSS.
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et al., 2018), any advantage of individualized dosing seems to improve
the safety of treatment. Optimizing this, we especially need to improve
the ‘down-dosing’ of FSH in expected hyper-responders without losing
their potential to have sufﬁcient oocyte yields. The objective of the
study was to increase the proportion of patients with the intended
retrieval of 5–14 oocytes using an AMH-based dosing algorithm.
Materials andMethods
Participants
This was a dual-center, RCT comparing patients treated in an individua-
lized AMH-based FSH dosing algorithm with patients treated with a stand-
ard FSH dose of 150 IU/day.
Infertile patients were included prior to their ﬁrst IVF or ICSI cycle from
the Fertility clinics at Rigshospitalet and North Zealand Hospital, during
the period January 2013 to November 2016. North Zealand Hospital func-
tioned as a satellite IVF clinic. All oocyte retrievals and single blastocyst
transfers were performed centrally at Rigshospitalet. In total 221 women
were randomized.
The main inclusion criteria were: indication for IVF or ICSI; ﬁrst treat-
ment at the clinic; age ≥25 and ≤38 years; serum AMH 4–40 pmol/L; nor-
mal menstrual cycles of 24–35 days interval presumed to be ovulatory;
bodyweight <75 kg; two ovaries accessible to oocyte retrieval; uterus with
presumed normal function based on sonography; and willingness and abil-
ity to sign the informed consent.
The main exclusion criteria were anovulatory polycystic ovary syn-
drome, endometriosis grade III/IV, hydrosalpinx on ultrasound, recurrent
miscarriages (≥3), FSH >12 IE/L and major medical disorders. There were
no restrictions in terms of BMI.
Screening was carried out on Days 2–5 of the menstrual cycle within 3
months prior to start of stimulation. Screening involved transvaginal ovar-
ian sonography with measurement of ovarian volume and counting of
antral follicles below 10 mm diameter.
Treatment
Participants were randomized at Day 3 of a spontaneous menstrual bleed-
ing. All patients fulﬁlling the criteria for participation were randomized in a
2:1 distribution between the individualized and standardly dosed groups.
Ovarian stimulation with FSH was started on Day 3 in an antagonist cycle.
Individualized group
Patients were FSH-dosed as follows: High AMH (>24 pmol/L) had minimal
dosing of 100 IU/day (rFSH; Puregon®, Organon, The Netherlands).
Normal AMH (12–24 pmol/L) had standard dosing of 150 IU/day (rFSH;
Puregon®). Low AMH (<12 pmol/L) had maximal dosing using corifollitro-
pin (Elonva® 100 or 150 μg according to bodyweight below or above
60 kg, Elonva®; Merck Sharp & Dohme B.V., Kenilworth, NJ, USA).
Standard group
All patients had rFSH (Puregon® 150 IU/day) irrespective of AMH levels.
For all patients in both arms a ﬁxed dose regiment was used throughout
the stimulation period. In two patients (one in each group) the clinician
decided to decrease the FSH dose at Day 8 due to risk of OHSS.
From Day 6 the GnRH antagonist ganirelix (Orgalutran®, Merck Sharp
& Dohme B.V., USA) 0.25 mg/day was administered s.c. once daily.
Patients stimulated with corifollitropin started GnRH antagonist on Day 5.
Criterion for triggering of ovulation with hCG (Ovitrelle® 250 μg, Merck
Serono Europe Limited, London, UK) was three follicles ≥17 mm.
Triggering could be done on that day or one day after. If less than three
mature follicles were present and the clinician had no expectation that
more mature follicles could be achieved, triggering and oocyte retrieval
versus IUI was discussed. Patients treated with corifollitropin (Elonva®)
were given rFSH 200 IU/day in those cases that continued stimulation
beyond Day 8. Patients were examined with sonography and baseline
blood sampling of FSH, LH, estradiol, progesterone and AMH.
All had luteal support using vaginal progesterone (Lutinus® 100 mg three
times a day for 14 days, Ferring Pharmaceuticals, Saint-Prex, Switzerland),
starting 2 days after oocyte retrieval and continued until the day of hCG-
testing. Vaginal progesterone was withdrawn in all patients on the day of
hCG-testing, 14 days after blastocyst transfer.
A single blastocyst was transferred at Day 5 after retrieval. If a blastocyst
was not available a compacted embryo could be transferred. Outcome of
pregnancy was recorded for all fresh cycle transfers and additionally from
all frozen embryo transfers (FET) of cryopreserved blastocysts transferred
within 1 year after ﬁnal patient enrollment.
From Day 5 after oocyte retrieval and onwards, patients daily assessed
their general wellbeing in terms of abdominal distention, abdominal pain
and dyspnea ranging on a scale of none, mild, moderate or severe.
Additionally, they answered if bleeding occurred until the day of the hCG-
testing.
Primary end point
The primary end point was the proportion of patients in the individualized
group versus the standard group who had an intended (5–14) versus an
unintended (<5 or ≥15) number of oocytes retrieved.
Unintended responses included patients who had oocyte retrieval can-
celed due to insufﬁcient response, excessive number of follicles, or had
canceled their blastocyst transfer due to freezing of all blastocysts in order
to avoid OHSS. No member of the trial initiators performed the oocyte
retrievals.
Secondary end points
Additionally, the trial examined the effect of individualization on the rates
of excessive response (>15 oocytes), OHSS occurrence, pregnancy,
ongoing pregnancy (>7 weeks’ gestation) and live birth as well as the sub-
jective wellbeing of patients in the luteal phase of treatment.
Randomization
Randomization was performed by a computer-generated randomization
list and the classical sealed envelope system, where the next numbered
envelope was taken for each new randomized patient. Randomization was
arranged using a variable block-size with either nine or six in the block, and
a 2:1 distribution of randomization between the individualized and stand-
ardly dosed patients. The practical procedure was undertaken by a person
that was independent of the doctor responsible for the treatment.
Participants were randomized at Day 3 of the cycle when the ovarian
stimulation was started.
AMH analysis
Serum AMH was measured using the Immunotech RIA AMH/MIS kit
(catalog number A16507, ELISA, Enzyme ImmunoAssay, Beckman
Coulter, France, with intra- and inter-assay coefﬁcients of variation ≤12.3
and ≤14.2%, respectively) from study start to 1 June 2015. Hereafter, the
fully automated Elecsys AMH Assay (Elecsys, intra- and inter-assay coefﬁ-
cients of variation ≤1.8 and ≤4.4%, respectively, Roche, Switzerland) was
used. The Immunotech assay was used in 154 patients (57%) and the
Elecsys in 115 patients (43%). In our clinic, a previous analysis of more than
400 samples with both assays found a conversion factor of 0.8. Therefore,
Elecsys-derived values were 0.8 of the value obtained with Immunotech.
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As a result, the cut-off levels between low, intermediate and high AMH in
the ﬁrst 154 patients were 15 and 30 pmol/L whereas the cut-offs were
12 and 24 pmol/L in the 115 patients included after the change of analysis.
All AMH values in the present article are expressed as with the Elecsys
assay.
Sample size and statistical analyses
We used data from our own earlier trial (Popovic-Todorovic et al., 2003)
where patients in the comparator arm were given a dose of 150 IU of
rFSH (Puregon®) and where 65% of the patients had an intended response
(5–14 oocytes), whereas 35% had unintended response. Calculation of the
sample size assumed that individualized dosing based on AMH would
reduce unintended responses by 50%, from 35 to 17.5%. In our earlier
study we observed a reduction from 35 to 25%, mainly due to no reduc-
tion in excessive responders following rFSH doses around 125 IU/day. In
the present study, we decided to lower the dose of rFSH to 100 IU/day in
patients with a predicted high response. We assumed it would be realistic
to reduce the proportion of unintended responses to 17.5%. This would,
when using a 2:1 randomization, require 216 patients, 144 in the individua-
lized and 72 patients in the standard arm (80% power, 5% signiﬁcance).
The Chi2-test, Student’s t-test and Mann–Whitney U test were used for
different comparisons, as appropriate. Statistically signiﬁcant differences
were set at P < 0.05. Data analysis was based on an intention-to-treat
(ITT) analysis. In terms of oocyte yield and embryo development, data are
related to the number who had oocyte retrieval (numbers speciﬁed in
Table II). Parameters of success (pregnancy, ongoing, live birth) and risk
(OHSS) were reported in the ITT population. Complete case analyses
were used in all calculations as data including the primary outcome mostly
considered counts, proportions and means. To test whether the scarce
missing data had any effect on the results, multiple imputation (Donders
et al., 2006) was carried out using the mice statistical package in R (Rstudio
Software, version 1.0.136). The pmm method was applied for continuous
and the polyreg for categorical variables. After imputation, no statistically
signiﬁcant alterations to the data were seen, hence results are reported as
a complete case analysis.
Prior to ﬁrst patient enrollment, the study was enrolled in the
EUDRACT online registry (2012-004969-40). The Scientiﬁc Ethical
Committee of the Copenhagen Region and the Danish Data Protection
Agency approved the study in December 2012 (H-3-2012-149 and 30-
0895, respectively). The study was monitored by the Good Clinical
Practice Unit (GCP) of the Danish Capital Region. All participants provided
a written informed consent to participation.
Results
Eligibility was assessed in 269 women and 221 were eventually rando-
mized to either the individualized (N = 149) or the standard (N = 72)
group. Each group was evenly distributed by their pretreatment AMH
levels between the low, medium and high strata (individualized group:
22.1, 55.4, 23.5% and standard group: 27.8, 47.2, 25.0%, respectively).
Table I shows baseline pretreatment characteristics between the
individualized and the standard group including the pretreatment
AMH, FSH, AFC and AMH/AFC values in the three AMH strata.
Figure 1 shows the ﬂow of patients through the trial. A similar pro-
portion of started cycles had oocyte retrieval (individualized group
146/149 (98%); standard group 71/72 (99%)). Oocyte retrieval can-
cellation due to inadequate response was seen in two cases in the indi-
vidualized and one case in the standard group. Considering the
patients who had oocytes retrieved, a similar proportion of the two
groups had blastocyst transfer (122/146, 82%; versus 56/71 (79%) in
the individualized and standard group, respectively).
Table II reports all primary and secondary outcomes including
between-group standardized mean differences and their 95% CI.
Table II shows the mean number of oocytes retrieved per pretreatment
AMH strata. In the individualized group the low AMH stratum had more
oocytes retrieved compared with the standardly dosed (7.3 ± 3.6 versus
5.1 ± 3.3, P = 0.04, respectively). Conversely, in the high AMH stratum
fewer oocytes were retrieved in the individualized group (6.3 ± 3.5 ver-
sus 10.6 ± 3.6, P < 0.01, respectively). Also shown in Table II, the
intended outcome of 5–14 oocytes was near equally achieved in the indi-
vidualized versus the standard group (72% [95% CI: 64–79%] and 78%
[95% CI: 67–86%], respectively). In the individualized group 23% (95%
CI: 17–31%) of patients had a low response (<5 oocytes) and 4.8% (95%
CI 2–9%) had a high response (≥15 oocytes) versus 18% (95% CI:
11–29%) and 4.2% (95% CI: 1–11%) in the standard group, respectively.
None of these differences were statistically signiﬁcant.
Figure 2 shows the relative distribution of oocytes retrieved per pre-
treatment AMH strata in the two study groups. For patients in the high
pretreatment AMH stratum exposed to individualized dosing of
100 IU/day, 38% (95% CI: 23–55%) had an unintended low response
(<5 oocytes) compared to only 6% (95% CI: 0.3–24%) of standard
group patients within this AMH stratum who had 150 IU/day (P =
0.029). Scrutinizing the individualized group, the 13 patients in the high
AMH stratum who had less than ﬁve oocytes compared with the 20
high AMH patients who had the intended response (5–14 oocytes)
there were no statistically signiﬁcant differences in terms of mean age
(31.9 ± 3.8 versus 32.6 ± 3.0 years), weight (61.8 ± 8.1 versus 61.6 ±
7.2 kg) or BMI (21.6 ± 2.3 versus 21.7 ± 1.8 kg/m2) or median AMH
levels within the stratum (33.0 [inter-quartile range (IQR) 29.6–35.2]
pmol/L versus 29.8 [IQR 26.9–34.0] pmol/L), pretreatment FSH
levels (7.5 [IQR 6.3–9.3] versus 7.2 [IQR 6.8–7.7] U/L) or the AMH/
AFC ratio (1.1 ± 0.3 versus 1.4 ± 0.4, P = 0.074).
In terms of an unintended high response within this stratum, there
was no statistically signiﬁcant difference. Conversely, among patients in
the low pretreatment AMH stratum treated with individualized dosing
using corifollitropin, the proportion of unintended low responders was
reduced to 24% (95% CI: 12–40%) compared with 47% (95% CI:
26–69%) in the standard group. This difference was not signiﬁcant
(P = 0.10).
Table II also shows that the number of aspirated follicles on the day
of oocyte retrieval was evenly distributed between groups and the fer-
tilization rate was marginally improved in the individualized group (P =
0.04). The number of embryos available as well as the number and
grading of blastocysts were similar between groups (grading data not
shown).
In two patients, both in the individualized group, all blastocysts were
frozen. One of these had early onset OHSS, the other had symptoms
of infection at the day of transfer. Both patients had a subsequent
transfer of a thawed blastocyst. Excessive responses comprised 4.8
versus 4.2%, comparing the individualized with the standard group,
respectively. GnRH agonist triggering was not used. In the individua-
lized group two of 149 patients (1.3%) had OHSS. One patient from
the medium AMH-stratum had severe early onset OHSS, cryopreser-
vation of all blastocysts and required 2 days of hospitalization, and one
patient in the low AMH-stratum had late onset moderate OHSS with-
out hospitalization. In the standard group, 2 of 72 (2.8%) patients
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developed OHSS. Both originated from the high AMH stratum and
had late onset moderate OHSS during early pregnancy without
hospitalization.
All clinical outcomes were similar. The live birth rate per single
blastocyst transfer was 34% (95% CI: 26–42%) and 38% (95% CI:
26–51%) and as seen in Fig. 1 the live birth rate per started cycle was
28% (95% CI: 21–35%) versus 29% (95% CI: 20–40%) in the individua-
lized versus the standard group, respectively. Similar proportions of
the randomized patients had blastocysts available for cryopreservation
(21% in the individualized and 20% in the standard group). As shown in
Fig. 1 and Table II, 22 of 30 patients with cryopreserved blastocysts in
the individualized group had a FET cycle and 6 (27%) had live births. In
the standard group, 7 of 14 patients had a FET cycle and 4 (57%) had
live births. All results were statistically non-signiﬁcant. Overall, the
cumulative live birth rate per started cycle was similar (32 and 35%)
comparing the individualized with the standard group.
Missing data were scarce regarding these main objective data as only
ﬁve women did not have an ovarian volume estimation and data on
the number of follicles at day of aspiration were missing in eight cases.
Performing multiple imputation on these values did not change the
ﬁndings in Tables I and II.
Table III shows subjective discomforts during the luteal phase with no
differences between the individualized and standard group regarding
abdominal distention, abdominal pain, dyspnea and bleeding pattern.
Complete data were collected from 78% of participants and are shown.
Missing data were mostly caused by lack of blastocyst transfers and thus
subsequent poor compliance of the patients. To test for the effect of this
large proportion of missing data, both multiple imputation and classifying
the missing values as an individual level within the categories was done.
Neither method showed statistically signiﬁcant changes to the results.
Discussion
Individualized AMH-based FSH dosing in the antagonist protocol using
the selected algorithm did not increase the proportion of patients with
an intended oocyte retrieval (5–14).
Comparing the intervention group exposed to individualized dosing
with the standardly dosed group, patients in the low AMH segment
had signiﬁcantly more (7.3 ± 3.6 versus 5.1 ± 3.3) oocytes retrieved,
whereas the patients in the high AMH segment had signiﬁcantly less
(6.3 ± 3.5 versus 10.6 ± 3.6). However, despite these apparently
favorable changes in terms of beneﬁts to risk ratio, the overall propor-
tions of patients who responded within the predeﬁned intended target
were similar, with 72% in the individualized group and 78% in the
standard group. Likewise, unintended responses deﬁned as either too
few (<5) or too many (≥15) oocytes were equal. Among patients with
a high AMH-based ovarian reserve, the reduction in rFSH dose to
100 IU/day in the individualized group displayed unwanted conse-
quences as 38% of these patients had less than ﬁve oocytes.
Therefore, if AMH is used alone for individualized rFSH dosing
100 IU/day is insufﬁcient, also in patients presumed to be able to have
a high response based on their AMH.
The 100 IU/day was based on our own earlier experience with an
RCT on rFSH dosing (Popovic-Todorovic et al., 2003) where around
...........................................
........................................................................................
Table I Baseline characteristics by individualized AMH-
based or standard dosing.
Type of dosing
Individualized Standard
N = 149 N = 72
Age (y), mean ± SD 32.2 ± 3.3 31.6 ± 3.2
Age groups, N (%) 29 (19.5) 21 (29.2)
<30 74 (49.7) 37 (51.4)
30–34
35–38 46 (30.9) 14 (19.4)
BMI (kg/m2), mean ± SD 22.2 ± 4.1 22.0 ± 2.6
Duration of infertility (months),
mean ± SD
27.3 ± 13.0 27.1 ± 10.3
Main cause of infertility, N (%)
Male 75 (50.3) 45 (62.5)
Tubal 14 (9.4) 4 (5.6)
Combined factors 4 (2.7) 1 (1.4)
Unexplained 56 (37.6) 22 (30.6)
Primary infertility, N (%) 103 (69.1) 54 (75.0)
Cycle length (d), mean ± SD 28.2 ± 1.8 28.1 ± 1.9
Ovarian volume (mL), mean ± SD 6.1 ± 2.6 6.2 ± 2.8
AFC, mean ± SD 20.3 ± 7.3 19.3 ± 7.5
AMH (pmol/L)*, median (IQR) 16.8 (12.0–23.0) 15.2 (10.6–23.5)
FSH (IU/L), median (IQR) 7.5 (6.2–8.9) 7.2 (6.1–8.4)
Treatment groups by AMH, N (%)
AMH 4–11.9 33 (22.1) 20 (27.8)
AMH 12–23.9 81 (55.4) 34 (47.2)
AMH 24–40 35 (23.5) 18 (25.0)
Pretreatment stimulation
characteristics by AMH stratum
AMH 4–11.9 pmol/L
AMH, median (IQR) 9.6 (6.6–10.7) 8.8 (6.6–9.6)
FSH, median (IQR) 7.8 (6.5–9.2) 7.2 (6.8–8.6)
AFC, mean ± SD 14.3 ± 4.8 12.9 ± 3.9
AMH/AFC 0.64 ± 0.18 0.68 ± 0.27
AMH 12–23.9 pmol/L
AMH, median (IQR) 16.8 (13.6–20.0) 15.6 (13.0–20.0)
FSH, median (IQR) 7.3 (6.2–9.0) 7.2 (6.2–8.8)
AFC, mean ± SD 19.7 ± 5.4 19.7 ± 6.0
AMH/AFC 0.93 ± 0.33 0.87 ± 0.20
AMH 24–40 pmol/L
AMH, median (IQR) 33 (28–35) 27 (24–29)
FSH, median (IQR) 7.3 (6.6–8.0) 6.0 (5.6–7.9)
AFC, mean ± SD 27.5 ± 7.3 25.8 ± 7.5
AMH/AFC 1.22 ± 0.06 1.17 ± 0.4
AMH, anti-Müllerian hormone; AFC, antral follicle count. No statistical differences
between groups using Student’s t-test, Mann–Whitney U test or Chi2-test as appro-
priate. *All serum AMH values in the present article are expressed as with the
Elecsys assay.
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125 IU/day was found not to lower the number of patients with
excessive responses. We assume some of this apparent discrepancy
may be related to the prior use of the long GnRH agonist protocol,
whereas the GnRH antagonist protocol was applied in the present
study. The recently published large Dutch multicenter ‘OPTIMIST’
study predominantly used GnRH agonist protocols and administered
100 IU/day of rFSH to expected high responders (AFC > 15). The
authors also reported a large number of poor responses (29%) and a
3-fold increase in cycle cancellation due to insufﬁcient follicular growth
(Oudshoorn et al., 2017).
The insufﬁciency of 100 IU/day of rFSH is likely caused by not reach-
ing the threshold for most follicles. In the early rFSH dose ﬁnding
studies after introduction of Puregon® on the market, ‘standard IVF
patients’ exposed to 100 IU/day had insufﬁcient follicle development
and cancellation of the cycle in as many as 24% of cases (Out et al.,
1999). These ﬁndings, our data and the recent studies on individualized
dosing show that 100 IU/day is insufﬁcient in a proportion of ‘standard
IVF patients’, as well as in predicted hyper-responding patients, irre-
spective of whether the prediction is based on AFC or AMH and irre-
spective of protocol used (Out et al., 1999; Oudshoorn et al., 2017).
Another factor inﬂuencing dosage is bodyweight, recently combined
with AMH in the dosing algorithm developed for the new follitropin
delta (Rekovelle®). In the large ESTHER-1 multicenter study (1326
patients), patients with AMH above 15 pmol/L were dosed per
.................................................
.............................................................................................................................................................................................
Table II Clinical outcome by individualized AMH-based or standard dosing.
Type of dosing
Individualized Standard
N = 146a N = 71a P SMD 95% CI
Follicles aspiratedb 8.6 ± 3.5 9.0 ± 4.3 0.23e −0.4 (−0.8 to 1.6)
Oocytes retrieved per pretreatment AMH (pmol/L)
Low (AMH 4–11.99) 7.3 ± 3.6 5.1 ± 3.3 0.04e 2.2 (0.2 to 4.1)
Normal (AMH 12–23.99) 8.1 ± 3.5 8.5 ± 3.3 0.58e −0.4 (−1 to 1.8)
High (AMH 24–40) 6.3 ± 3.5 10.6 ± 3.6 0.00e −4.3 (−6.4 to −2.1)
Total 7.5 ± 3.6 8.1 ± 3.9 0.25e −0.6 (−0.5 to 1.7)
Oocytes retrieved 0.68f
<5—unintended low 34 (23.3) 13 (18.3) 0.51g 5% (−7 to 17)
5–14—intended 105 (71.9) 55 (77.5) 0.48g −6% (−19 to 8)
≥15—unintended high 7 (4.8) 3 (4.2) 0.98g 0.6% (−6 to 9)
Duration of stimulation (d) 8.8 ± 1.4 8.2 ± 1.3 0.00e 0.6 (0.2 to 1.0)
Total FSH dose (IU)c 1.177 ± 262 1.239 ± 166 0.09e −62 (−23 to 111)
Fertilization
Fertilized oocytes 3.9 ± 2.5 3.7 ± 2.5 0.78e 0.2 (−0.9 to 0.5)
Rate of fertilization 54 ± 27 46 ± 28 0.04g 8% (16 to 0.01)
Embryo development
Embryos Day 2 4.1 ± 2.6 4.0 ± 2.7 0.82e 0.1 (−0.9 to 0.6)
Blastocysts Day 5 1.9 ± 1.6 1.9 ± 1.9 0.57e 0 (−0.5 to 0.5)
Blastocyst transfer 122 (83.6) 56 (78.9) 0.40f 4.7% (−8 to 17)
No transfer 24 (16.4) 15 (21.1)
OHSS any typed 2/149 (1.3) 2/72 (2.8) 0.73g 1.5% (−7 to 4)
Positive hCGd 57/149 (38.3) 32/72 (44.4) 0.34g −6.1% (−21 to 9)
Ongoing pregnancy (week 7)d 44/149 (29.5) 21/72 (29.2) 0.79g 0.3% (−13 to 14)
Live birthd
Per fresh cycle 41/149 (27.5) 21/72 (29.2) 0.79g −1.7% (−15 to 12)
Per FET 6/22 (27.3) 4/7 (57.1) 0.16g −30% (−80 to 20)
Cumulative 47/149 (31.5) 25/72 (34.7) 0.64g −3.2% (−17 to 11)
Values are mean ± SD and count (column %).
OHSS, ovarian hyperstimulation syndrome; FET, frozen embryo transfer; SMD, standardized mean difference.
aAnalyses for women who had oocyte retrieval. unless otherwise speciﬁed.
bMissing data on follicles aspirated (n = 8).
cFSH dose comparing medium and high pretreatment AMH-strata.
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kilogram (Nyboe Andersen et al., 2017) in order to allow better
‘down-dosing’ with rFSH. Indeed, this dosing model increased the pro-
portion of patients within the targeted number of oocytes (8–14).
To explore the insufﬁciency of 100 IU/day of rFSH, we compared
patients within the high AMH stratum who had <5 or 5–14 oocytes
retrieved in the present study. They did not differ in terms of age,
bodyweight, BMI, FSH or AMH levels or AMH/AFC ratio. In a large
American study on anovulatory infertility (Mumford et al., 2016) a high
AMH/AFC ratio predicted unresponsiveness to ovulation induction
and suggested that high intrafollicular AMH levels could diminish FSH
sensitivity. In the present study, we found the same trend among our
ovulatory patients in the high AMH stratum, as the ratio was increased
(1.4 ± 0.4) in the group who had <5 oocytes retrieved compared with
the group who had 5–14 (1.1 ± 0.3) (P = 0.07). However, our small
sample size limits conclusions regarding this hypothesis of high intrafol-
licular AMH levels as a cause of relative insensitivity to FSH stimulation
and since this outcome was not a predeﬁned end point, the result is
merely hypothesis developing.
This investigator-driven dual center study was not powered for such
rare events as excessive responses (>15 oocytes), OHSS or OHSS
related preventative actions such as cancellation of the oocyte
retrieval, agonist triggering or freeze all. The data showed no differ-
ence by choice of protocol. The OPTIMIST trials reported a statistic-
ally signiﬁcant increase (P = 0.002) in cycle cancellation due to
excessive responses comparing the daily dose of 150IU with 100IU,
albeit at the expense of a cancellation rate of 21% due to insufﬁcient
growth (Oudshoorn et al., 2017). The beneﬁts were an overall reduc-
tion of OHSS (all types). The ESTHER-1 trial using the antagonist
Figure 1 Patient ﬂow and outcome during the study of AMH-based individualized FSH dosing in a GnRH antagonist protocol,
from assessment of eligibility to cumulative live birth rate. AMH, anti-Müllerian hormone.
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protocol showed a reduction in excessive responses by individualiza-
tion and less patients with OHSS and OHSS preventive measures
(Nyboe Andersen et al., 2017). Accordingly, the recent meta-analysis
(Lensen et al., 2018) concluded that the beneﬁt of individual dosing
models could be a reduction in OHSS incidence.
We assessed the patient-reported subjective wellbeing during the
luteal phase in order to evaluate whether individualized dosing could
decrease the discomforts by reducing the number of hyper responses.
Unfortunately, 22% of ITT participants were lost to follow-up despite
being invited to return their questionnaires. Non-respondents predomin-
antly did not have a blastocyst transfer and therefore lost the incentive to
return. Within the patients who had a blastocyst transfer the data were
robust, in line with the randomization and we saw no improvement by
individualization. However, as the proportion of missing data was sub-
stantial caution in the interpretation of these results is warranted.
Although not statistically powered to analyze pregnancy rates, the
study found similar singleton ongoing pregnancy rates per transfer
(44/122 = 36% versus 21/56 = 38% comparing individualized with
standard group, respectively) and live birth per started cycle (28 versus
29%), suggesting neither beneﬁt nor harm of the individualized dosing
regimen, irrespective of which parameter was used. Additionally, the
cumulative live birth rates were similar at 32 and 35% after completion
of FET cycles within 1 year of study completion, comparing individua-
lized with standard group, respectively.
A major limitation of this study was the change of AMH assay half-
way through the study period. Supplementary Figure S1 illustrates the
measured median and inter-quartile range pr. AMH stratum in each
assay and Supplementary Fig. S2 the dispersion of values with stratum
medians. All Immunotech values were converted to corresponding
Elecsys values using the 0.8 factor. Following this conversion, no statis-
tical differences were observed between the two assays. This change
was unexpected at the time of study design and introduce an obvious
methodological limitation. However, following the considerations of
the Supplementary ﬁgures, we feel conﬁdent that both assays gave suf-
ﬁciently comparable measures of AMH values for these to be pooled.
The expected extreme cases of ovarian stimulation (AMH < 4 and
> 40 pmol/L, FSH > 12 IU/L) and the patients with a bodyweight >
75 kg were excluded. This selection bias limits the generalizability of
Figure 2 Proportion of patients with a low, intended or high response in terms of oocytes retrieved according to pretreatment
AMH. (A) Individualized AMH-based dosing and (B) standard dosing. Difference in distribution within each AMH stratum was evaluated by a two pro-
portions z-test.
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our results but were chosen in this 2012-designed study for ethical
reasons to counteract extreme responses in the standard arm in which
all patients had 150 IU/day irrespective of their AMH (Arce et al.,
2014). The recently advanced understanding of this area (Nyboe
Andersen et al., 2017; Oudshoorn et al., 2017; Lensen et al., 2018)
suggests a different setup and it would have been interesting to see the
100 IU/day effect on the patients with AMH > 40 pmol/L.
Likewise, predeﬁning cut-off levels for AMH subgroups is debatable.
The present study based the cut-off levels on previous work using the
Immunotech assay, suggesting a pragmatic and clinically applicable model
with regard to prediction of both oocytes and live birth rate (Nelson
et al., 2007). Our cut-off for more aggressive stimulation with corifolli-
tropin (Elonva®) was based on earlier uncontrolled studies using AMH
to determine protocol and FSH doses (Nelson et al., 2009; Yates et al.,
2011). In our study, the predeﬁned cut-offs corresponded to quartiles
of the population as ~25% had an AMH < 12 pmol/L, 50% between 12
and 24 pmol/L, and 25% > 24 pmol/L. Similar cut-offs were used by
Anckaert et al. (2012) relating the responses and OHSS risks to these
AMH quartiles. As a clinically applicable model we therefore ﬁnd merit
in this division. Recent trials on individualization chose to dose according
to the AMH range (Allegra et al., 2017; Nyboe Andersen et al., 2017)
and this offers a novel way to examine the concept.
In our center, substantial experience with corifollitropin (Elonva®)
stimulation is available. Previously, we presented the analysis of 599 sti-
mulations cycles with no OHSS cases, when the drug was selectively
given to patients with AMH in the lower AMH segment (Nielsen et al.,
2016). Instead of using a high daily dose of rFSH for the low AMH stra-
tum in the individualized group we chose to use corifollitropin due to
ease of administration, a lower cost for the patient and current evidence
suggesting an oocyte yield similar to 300 IU/daily of rFSH (Boostanfar
et al., 2016). Nonetheless, whether corifollitropin being introduced to a
subgroup of the intervention has introduced confounding cannot be
ruled out. Also, of the 34 women treated with corifollitropin, 25 needed
additional daily FSH doses of 200IU beyond Day 8 of stimulation (6
patients had 1 day, 11 had 2 days, 5 had 3 days and 3 had 4 days). It can
be argued that an addition of daily 300IU would have better mimicked
the corifollitropin dosage. However, considering empirical experience of
slight dosage changes beyond Day 8 of stimulation, we believe this
would be of a minor importance for the oocyte yield.
To our knowledge, this RCT is only the second of its kind to investi-
gate individualized dosing in a mandatory antagonist protocol with sin-
gle blastocyst transfers. As such, it helps to dispel doubts of the
concept. The trial was not blinded but none of the authors participated
in the oocyte retrievals that provided the primary end point.
Additionally, this trial set out to evaluate a concept without any prede-
termined preference within the investigators and so we would con-
sider any unblinding biases to the results to be negligible.
The clinical implication of administering 100 IU/day of rFSH in pre-
dicted hyper-responders is a large proportion of seemingly under-
dosed patients. As we are presently not able to predict who will
respond appropriately, this group could be dosed in the range




Table III Patient experiences during the luteal phase according to type of dosing and pretreatment AMH.







AMH-based Standard AMH-based Standard AMH-based Standard
Abdominal distension, P = 0.13
None 2 (7.1) 2 (13.3) 5 (8.3) 5 (17.2) 0 (0.0) 0 (0.0)
Mild 17 (60.7) 5 (33.3) 29 (48.3) 13 (44.8) 11 (40.7) 4 (30.8)
Moderate 5 (17.9) 8 (53.3) 19 (31.7) 10 (34.5) 10 (37.0) 6 (46.2)
Severe 4 (14.3) 0 (.0) 7 (11.7) 1 (3.4) 6 (22.2) 3 (23.1)
Abdominal pain, P = 0.90
None 4 (14.3) 2 (13.3) 7 (11.7) 2 (6.9) 3 (11.1) 0 (0.0)
Mild 11 (39.3) 5 (33.3) 28 (46.7) 15 (51.7) 16 (59.3) 7 (53.8)
Moderate 11 (39.3) 5 (33.3) 19 (31.7) 8 (27.6) 5 (18.5) 5 (38.5)
Severe 2 (7.1) 3 (20.0) 6 (10.0) 4 (13.8) 3 (11.1) 1 (7.7)
Dyspnoea, P = 0.21
None 17 (60.7) 13 (86.7) 41 (68.3) 20 (69.0) 11 (40.7) 9 (69.2)
Mild 10 (35.7) 2 (13.3) 16 (26.7) 7 (24.1) 11 (40.7) 2 (15.4)
Moderate 1 (3.6) 0 (0.0) 2 (3.3) 2 (6.9) 5 (18.5) 2 (15.4)
Severe 0 (0.0) 0 (0.0) 1 (1.7) 0 (0.0) 0 (0.0) 0 (0.0)
Grading of bleeding after transfer, P = 0.79
Menstruation 15 (83.3) 9 (81.8) 30 (73.2) 13 (68.0) 12 (75.0) 7 (77.8)
Spotting 3 (16.7) 2 (18.2) 11 (26.8) 6 (32.0) 4 (25.0) 2 (22.2)
Values are count and column proportions (%). No statistical differences between groups using Chi2-test.
Questionnaires were returned by 172 of 221 patients (22% missing data).
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speciﬁed hyper response group for testing the low dosage regimen.
However, the meta-analysis by Lensen et al. (2018) indicates that this
is unlikely to increase pregnancy rates and should be powered for a
safety outcome. Dosing with <150 IU/day also in the antagonist
protocol should otherwise be avoided in accordance with a recently
stated recommendation by the Editor in Chief of ‘Human
Reproduction’, Hans Evers (Evers, 2017). Optimizing the safety aspect,
hyper-responders may also beneﬁt from both agonist triggering and a
freeze-all approach. This concept currently await the results of ongoing
European RCTs (Stormlund et al., 2017).
Likewise, based on the present understanding it seems clear that
more aggressive FSH dosing in patients with a low or limited ovarian
reserve may squeeze out one or two more oocytes (Oudshorn et al.
2018; Nyboe Andersen et al., 2018) but this will also not increase
pregnancy rates. Herein we agree with the 2015 Broekmans argument
that one more oocyte will probably not produce any beneﬁt for the
live birth rate (Broekmans, 2015).
The main ﬁndings in the present study are rather consistent with
recently published multicenter trials. Individualized FSH dosing induce
minor changes in oocyte numbers in patients with low and high AMH,
but these changes improve neither pregnancy nor live birth rates.
Supplementary data
Supplementary data are available at Human Reproduction Open online.
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